News | FFR Technologies | August 28, 2017

Philips to Develop FFR-Angiography in Partnership With HeartFlow

Global collaboration aims to accelerate access to tools to determine extent of coronary artery disease and improve patient care

Philips is partnering with HeartFlow to co-develop new FFR-CT and FFR-angiography imaging technologies.

August 28, 2017 — Philips Healthcare and HeartFlow Inc. announced they entered into a collaboration agreement to improve access to diagnostic and planning tools for interventional cardiologists evaluating and treating patients with suspected coronary artery disease (CAD). Under the agreement, Philips will promote the use of the HeartFlow FFR-CT analysis in conjunction with Philips' advanced catheters for imaging and assessing measurements of the inside of a patient's coronary arteries. 

The advanced catheters from Philips that will be promoted in conjunction with HeartFlow's technology include Philips' coronary fractional flow reserve (FFR), instant wave-free ratio (iFR) and intravascular ultrasound (IVUS) solutions.

Philips and HeartFlow's commercial collaboration will initially focus on the United States, with the intention to expand joint efforts globally in the near term. The two companies are also exploring further collaborations in diagnostic imaging and advanced informatics.

The HeartFlow FFR-CT analysis is the only commercially available noninvasive technology to provide insight into both the extent of CAD and the impact of the disease on blood flow to the heart. Data from a patient's non-invasive coronary CT angiogram are securely uploaded from the hospital's system to the cloud. HeartFlow leverages deep learning to create a personalized, digital 3-D model of a patient's coronary arteries, which is then analyzed by powerful computer algorithms to evaluate millions of complex equations to simulate blood flow in the model and assess the impact of blockages on coronary blood flow. The HeartFlow technology provides results to the clinician via a secure web interface. To date, more than 13,000 patients have benefitted from the HeartFlow FFR-CT analysis.[1]

In the United States, 16.8 million people are affected by CAD, which develops when the coronary arteries narrow, reducing blood flow to the heart.[2] CAD causes chest pain and heart attack and can lead to death. As part of a standard protocol, many of these patients are referred to the cardiac cath lab where more than half are discharged on medicines or non-treatment. Improvements in the non-invasive space have the potential to allow physicians to safely defer invasive testing, reducing risks to the patient and the overall cost of care for all.

"Our commitment is to transform the patient experience and identify pathways that are personalized, high quality and at a lower price point," said Christopher Barys, business leader of Philips image guided therapy devices. "To address the burden that CAD is placing on healthcare systems and to transform the patient experience, hospitals are focused on adopting new technology that can improve the diagnosis and care of these patients while reducing unnecessary invasive procedures. HeartFlow shares our mission of improving clinical outcomes and, through collaboration, we can advance our goal of helping healthcare providers decide, guide, treat and confirm the right therapy at the point of care."

Exclusive Agreement to Co-develop FFR-Angiography

In addition to the commercial collaboration agreement between Philips and HeartFlow, the two companies have entered into an exclusive agreement to co-develop an improved cath lab X-ray angiography image derived FFR or iFR solution, to significantly enhance workflow while improving the diagnosis and subsequent treatment of patients with CAD. The solution will use angiographic imaging to create a derived FFR,  similar to FFR-CT technology.

"Our collaboration agreement with Philips, which has an integrated solution within cath labs, will help bring HeartFlow's technology to more patients with suspected and potentially life-threatening CAD," said John H. Stevens, M.D., president and CEO of HeartFlow. "We look forward to continuing to address unmet needs in cardiology in collaboration with Philips to further support our goal of improving patient lives and reducing the total cost of care."

Philips' seamlessly integrated solutions, such as CORE IVUS and SyncVision, are valuable tools in the diagnosis of CAD. The HeartFlow FFRct Analysis, is an additional diagnostic tool that expands clinicians' capabilities.

For more information: www.philips.com/newscenter

 

Related FFR and FFR-CT Content:

What is New in FFR Technology

GE Healthcare, HeartFlow Announce Cardiovascular CT Collaboration for FFR-CT

VIDEO: Implementation and the Science Behind FFR-CT

 

References: 

1. Douglas PS, DeBruyne B, Pontone G., Patel MR, et al. One-year outcomes of FFRCT-guided care in patients with suspected coronary disease: The PLATFORM Study. J Am Coll Cardiol. 2016;68(5),435-45. 

2. www.ncbi.nlm.nih.gov/pmc/articles/PMC2787400/

Related Content

Toshiba Vantage Galan 3T XGO Edition MRI Features New Advanced Gradient
Technology | Magnetic Resonance Imaging (MRI)| December 11, 2017
Toshiba Medical, a Canon Group company, demonstrated the Vantage Galan 3T XGO Edition with the all-new Saturn X...
CorInnova Awarded 2017 InnoSTARS Prize for EpicHeart Soft Robotic Heart Assist Device
News | Artificial Heart| December 11, 2017
CorInnova Inc. recently announced it was awarded second prize in the “2017 InnoSTARS” life science competition for its...
Philips Debuts IQon Elite Spectral CT Scanner at RSNA 2017
Technology | Computed Tomography (CT)| December 11, 2017
At the 2017 Radiological Society of North America (RSNA) Annual Meeting, Philips unveiled the IQon Elite Spectral CT,...
Videos | Advanced Visualization| December 07, 2017
Dianna Bardo M.D., director of body MR and co-director of the 3-D Innovation Lab at Phoenix Children's Hospital.
Edwards Acquires Harpoon Medical
News | Heart Valve Technology| December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Toshiba Highlights Ultra-High Resolution CT at RSNA 2017
News | Computed Tomography (CT)| December 06, 2017
Toshiba Medical, a Canon Group company, showcased the Aquilion Precision, what it calls the world’s first ultra-high...
Robocath Receives $1.5 Million in Capital for Advancement of R-One Robotic System
News | Robotic Systems| December 06, 2017
December 6, 2017 — French company Robocath, which designs and develops...
New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

Feature | December 06, 2017 | Dave Fornell
Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC) magaz
New Tool Predicts Risk of Heart Attack in Older Surgery Patients
News | Cardiac Diagnostics| December 05, 2017
A tool designed to more accurately predict the risk of heart attack in older patients undergoing non-cardiac surgery...
Toshiba Launches Vantage Elan Zen Edition MR for Enhanced Patient Comfort
Technology | Magnetic Resonance Imaging (MRI)| December 05, 2017
Toshiba Medical, a Canon Group company, introduced its newest magnetic resonance (MR) system, the Vantage Elan/Zen...
Overlay Init